Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy DOI
Florentia Dimitriou, Sabrina A. Hogan, Alexander M. Menzies

et al.

European Journal of Cancer, Journal Year: 2021, Volume and Issue: 157, P. 214 - 224

Published: Sept. 15, 2021

Language: Английский

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma DOI Creative Commons
Rik J. Verheijden,

F.H. Burgers,

Josephine C Janssen

et al.

European Journal of Cancer, Journal Year: 2024, Volume and Issue: 207, P. 114172 - 114172

Published: June 15, 2024

Language: Английский

Citations

17
AND-gated protease-activated nanosensors for programmable detection of anti-tumour immunity DOI
Anirudh Sivakumar, Hathaichanok Phuengkham,

Hitha Rajesh

et al.

Nature Nanotechnology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Language: Английский

Citations

2
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19 DOI Creative Commons
Philip C. Robinson, David Liew, Jean W. Liew

et al.

Med, Journal Year: 2020, Volume and Issue: 1(1), P. 90 - 102

Published: Dec. 1, 2020

Language: Английский

Citations

120
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors DOI Creative Commons
Xiaohui Jia, Luying Geng, Panpan Jiang

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2020, Volume and Issue: 39(1)

Published: Dec. 1, 2020

Abstract The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) obstacle to prospect ICI treatment. IrAEs are a discrete toxicity caused by nonspecific activation system and can affect almost all tissues organs. Currently, research biomarkers mainly focuses gastrointestinal tract, endocrine system, skin lung. Several potential hypotheses concentrate overactivation excessive release inflammatory cytokines, elevated levels pre-existing autoantibodies, presence common antigens between tumors normal tissues. This review lists current that might predict irAEs possible mechanisms both organ-specific biomarkers. However, prediction remains major clinical challenge screen identify patients who susceptible likely benefit ICIs.

Language: Английский

Citations

97
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy DOI
Florentia Dimitriou, Sabrina A. Hogan, Alexander M. Menzies

et al.

European Journal of Cancer, Journal Year: 2021, Volume and Issue: 157, P. 214 - 224

Published: Sept. 15, 2021

Language: Английский

Citations

92